Norris Comprehensive Cancer Center, University of Southern California, 1441 Eastlake Ave. Suite 3440, Los Angeles, CA, 90033, USA.
Columbia University Medical Center, New York, NY, USA.
Arch Osteoporos. 2019 Jul 28;14(1):83. doi: 10.1007/s11657-019-0629-7.
To explore the rates of osteoporosis (diagnosis and screening) and fractures in colorectal cancer survivors (CRCS), records of clinical trial enrollees was linked to Medicare. Female/male risk of fracture in CRCS is 74% higher than general population. Less than 30% of male and female CRCS receive osteoporosis screening. Osteoporosis is a significant morbidity in CRCS.
In the USA, the population of colorectal cancer survivors (CRCS) is on the rise. Calcium and vitamin D are the common thread between colorectal cancer and osteoporosis. We set to explore the patterns and prevalence of osteoporosis (OP) and osteoporotic fractures (OF) in CRCS who received fluorouracil-based therapy on SWOG trials.
Data for CRCS from three SWOG phase III treatment trials between 1994 and 2000 (N = 3775) were linked to Medicare claims (N = 1233). OP was identified using ICD9 and HCPCS codes; OF was defined using a more restricted set of codes. We compared patterns of OP, OF, and screening for OP by gender in CRCS. Given the gender disparities in the rates of OP and OF, we used data from the National Health Interview Survey (NHIS) and the National Hospital Discharge Survey (NHDS) to assess the ratio of OF in females and males in general population.
Forty-seven percent of females and 15% of men CRCS had OP claims. Female CRCS were more likely than males to have OP (HR = 4.76 [3.77-6.01], p < 0.0001) and OF (HR = 2.64 [2.04-3.42], p < 0.0001). In the general population, the female to male ratio of OF was 1.67 as opposed to 2.90 in CRCS, indicating a significantly larger gender disparity of OF in CRCS (p < 0.001). Only 7% of men and 27% of women CRCS had OP screening.
Despite a low rate of OP screening, the gender disparity of OF in CRCS is more pronounced than the general population. These findings provide an impetus for studying OP and OF in CRCS.
探索结直肠癌幸存者(CRCS)的骨质疏松症(诊断和筛查)和骨折发生率,将临床试验参与者的记录与医疗保险相关联。CRCS 女性/男性骨折风险比普通人群高 74%。不到 30%的男性和女性 CRCS 接受骨质疏松症筛查。骨质疏松症是 CRCS 的一种严重发病率。
在美国,结直肠癌幸存者(CRCS)的人数正在增加。钙和维生素 D 是结直肠癌和骨质疏松症之间的共同因素。我们旨在探索接受 SWOG 试验氟尿嘧啶为基础的治疗的 CRCS 中骨质疏松症(OP)和骨质疏松性骨折(OF)的模式和流行率。
将 1994 年至 2000 年期间进行的三项 SWOG 三期治疗试验的 CRCS 数据(N=3775)与医疗保险索赔(N=1233)相关联。使用 ICD9 和 HCPCS 代码识别 OP;使用更严格的一组代码定义 OF。我们比较了 CRCS 中 OP、OF 和 OP 筛查的性别模式。鉴于 OP 和 OF 发生率的性别差异,我们使用国家健康访谈调查(NHIS)和国家医院出院调查(NHDS)的数据来评估一般人群中女性和男性 OF 的比率。
47%的女性和 15%的男性 CRCS 有 OP 索赔。女性 CRCS 比男性更有可能发生 OP(HR=4.76[3.77-6.01],p<0.0001)和 OF(HR=2.64[2.04-3.42],p<0.0001)。在一般人群中,OF 的女性与男性比例为 1.67,而 CRCS 中的比例为 2.90,表明 CRCS 中 OF 的性别差异明显更大(p<0.001)。只有 7%的男性和 27%的女性 CRCS 进行了 OP 筛查。
尽管 OP 筛查率较低,但 CRCS 中 OF 的性别差异比一般人群更为明显。这些发现为研究 CRCS 中的 OP 和 OF 提供了动力。